Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
March 09 2016 - 7:46PM
Hagens Berman Sobol Shapiro LLP, a national investor-rights law
firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors
there is a March 14, 2016 lead plaintiff deadline in the securities
fraud class action lawsuit filed against the Company related to the
delayed approval of Esperion’s leading cholesterol drug.
If you suffered losses because of your purchases of
Esperion securities between August 18, 2015 and September 28, 2015,
contact Hagens Berman Partner Reed Kathrein, who is leading the
firm’s investigation by calling 510-725-3000,
emailing ESPR@hbsslaw.com or visiting
https://www.hbsslaw.com/cases/ESPR. The lawsuit was filed in
the U.S. District Court for the Eastern District of Michigan and
investors have until March 14, 2016 to move the court to
participate as a lead plaintiff.
Esperion Therapeutics is a pharmaceutical company focused on
developing drugs to lower LDL cholesterol. According to the
complaint, by early August 2015, Esperion completed Phase 2b
clinical trials for its leading product candidate, ETC-1002, and
was meeting with the FDA to discuss moving forward with the Phase 3
segment of the approval process. On August 17, 2015, Esperion
relayed to investors material events from its meeting with the FDA,
and stated that the FDA informed the company that it would not have
to complete rigorous cardiovascular trials in order to gain
approval of ETC-1002. Esperion further stated that the company was
pleased with the outcome of the meeting and that the FDA gave it a
“clear regulatory path forward for development and approval of
ETC-1002.”
Then on September 28, 2015, Esperion reversed course about the
FDA meeting, stating that the FDA had actually encouraged the
company to initiate a cardiovascular trial and it may be necessary
to complete these trials before ETC-1002 would be approved. On this
news, Esperion stock fell by $16.76 per share, or nearly 50%, to
close at $18.33 per share on September 29, 2015. The share price
has continued to fall. The complaint alleges Esperion misled
investors when they made statements about the FDA meeting that they
reversed in later announcements.
Whistleblowers: Persons with non-public
information regarding Esperion should consider their options to
help in the investigation or take advantage of the SEC
Whistleblower program. Under the new SEC whistleblower program,
whistleblowers who provide original information may receive rewards
totaling up to 30 percent of any successful recovery made by the
SEC. For more information, call Reed Kathrein at
510-725-3000 or email ESPR@hbsslaw.com.
About Hagens Berman
Hagens Berman is headquartered in Seattle, Washington with
offices in 10 cities. The Firm represents investors,
whistleblowers, workers and consumers in complex litigation. More
about the Firm and its successes can be found at www.hbsslaw.com.
Read the Firm’s Securities Newsletter, and visit the blog. For the
latest news visit our newsroom or follow us on Twitter at
@classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024